Several new treatment options for chronic illnesses have received FDA approval in the last few months. Among them are two biologic agents administered intravenously for chronic refractory gout in adults (September 2010)  and the other is for Lupus, a serious autoimmune disorder (March 2011). Krystexxa (pegloticase) has been approved by the FDA  for patients with…